Charles River Laboratories (CRL) investor relations material

Leadership transition and strategic focus

• New CEO emphasizes making the organization simpler, with better margins and growth, rolling out the 'Pathway to Purpose' strategy and executing divestitures and cost savings initiatives.

• Two business divestitures completed in May, focusing on core, higher-value, regulated work.

• Over $100 million in cost savings targeted for 2024, with $300 million cumulative over recent years.

• Margin improvement of 120-150 basis points expected in 2024, with potential for 500 basis points in H2.

• Balanced capital allocation includes $200 million in Q1 stock repurchases and reaffirmed guidance.

Technology, AI, and NAMs integration

• AI and automation are being embedded to drive efficiency, competitiveness, and margin improvement.

• Significant investment in NAMs (New Approach Methodologies) to reduce animal use, including the AMAP initiative and acquisition of PathoQuest.

• Over 1,000 companies are developing NAMs, but integration into safety assessment is key for competitive advantage.

• NAMs will supplement, not replace, animal studies, providing additional data and reducing animal use in specific contexts.

• PathoQuest's next-generation sequencing aims to replace animal use in lot release testing.

Business performance and market outlook

• Demand stabilizing with biotech bookings at a two-year high and proposal volume up high single digits.

• DSA segment expected to return to growth in H2 2024, with gradual improvement seen.

• RMS business faces gradual volume decline due to industry trends, but pricing and higher-value models offset some impact.

• CRADL business impacted by weak biotech startup formation; NHP sales to third parties fluctuate.

• Manufacturing margins expected to return above 30% post-CDMO divestiture, with strong recurring revenue.